Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
-
REGULATORY Japan’s 1st Stelara, G-Lasta Biosimilars Nearing Finish Line
July 18, 2023
-
BUSINESS Gilead Japan Building Sales Force to Prep for Full Oncology Entry: Chief
July 14, 2023
-
REGULATORY Chuikyo Split over Drug Lags and Losses, Rapid Introduction Evaluation System
July 13, 2023
-
BUSINESS Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas
July 12, 2023
-
REGULATORY MHLW Pharma Regulation Panel Kicks Off, Agrees to Discuss Incentives to Develop Pediatric Drugs
July 11, 2023
-
BUSINESS Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023
-
ORGANIZATION Stop Requiring Japanese PI Data for Global Products: JPMA Officials
July 10, 2023
-
REGULATORY PMDA US Office to Set Out Solution for Drug Lag, Loss: Agency Chief
July 10, 2023
-
BUSINESS Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
July 10, 2023
-
BUSINESS FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
July 7, 2023
-
REGULATORY Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
July 6, 2023
-
REGULATORY Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
-
BUSINESS Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
July 5, 2023
-
BUSINESS Alarmed over Domestic Generics Biz, Sawai Group to Review Long-Term Targets
July 5, 2023
-
BUSINESS Jan Stefan Scheld to Helm Nippon Boehringer Ingelheim
July 5, 2023
-
BUSINESS Chugai Is Best-Paying Japan Pharma Again in FY2022, 5 Drug Makers Top 10 Million Yen
July 4, 2023
-
REGULATORY MHLW to Launch Pharma Affairs Study Group July 10, Drug Loss Up for Debate
July 4, 2023
-
REGULATORY LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation
July 3, 2023
-
BUSINESS 32 Pharma Execs Take Home Over 100 Million Yen in FY2022, Top 3 from Takeda: Securities Reports
July 3, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…